VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus. VBI is headquartered in Cambridge, MA with research facilities in Ottawa, Canada.
Epixis SA, a biotechnology company, engages in the development of advanced immuno-therapies based on recombinant virus-like particles against hepatitis C. The company was founded in 2003 and is based in Paris, France.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.